Astrazeneca (AZN) Stock Price, News & Analysis

Company Overview

AstraZeneca plc is a global biopharmaceutical company focused on the discovery, development and commercialization of prescription medicines. Its principal therapeutic areas include oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology conditions, and rare diseases.

The company’s portfolio includes medicines such as Tagrisso, Imfinzi and Lynparza for cancer; Farxiga for cardiovascular, kidney and metabolic conditions; Fasenra for severe asthma; and Symbicort for respiratory disease. AstraZeneca also develops vaccines, immune therapies and other biologic treatments through internal research and strategic partnerships.

AstraZeneca was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group. Headquartered in Cambridge, England, the company conducts research, manufacturing and commercial operations across numerous markets worldwide. Pascal Soriot has served as AstraZeneca’s chief executive officer since 2012.

Key Stats

• Today's Range: $158.13 to $161.51
• 50-Day Range: $155.79 to $192.77
• 52-Week Range: $145.79 to $212.71
• Volume: 2.22 million shs
• Average Volume: 3.14 million shs
• Market Capitalization: $248.11 billion
• P/E Ratio: 23.91
• Dividend Yield: 2.71%
• Price Target: $206.67
• Consensus Rating: Moderate Buy

Astrazeneca Stock Analysis - MarketRank™

Astrazeneca scored higher than 98% of companies evaluated by MarketBeat, and ranked 14th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Astrazeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on no strong buy ratings, 14 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Astrazeneca has a consensus price target of $206.67, representing about 29.2% upside from its current price of $159.98.

Amount of Analyst Coverage

Astrazeneca has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 12.74%

Earnings Growth

Earnings for Astrazeneca are expected to grow by 12.74% in the coming year, from $9.34 to $10.53 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Astrazeneca is 23.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 36.91.

Price to Earnings Ratio vs. Sector

The P/E ratio of Astrazeneca is 23.91, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 212.38.

Price to Earnings Growth Ratio

Astrazeneca has a PEG Ratio of 1.35. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Astrazeneca has a P/B Ratio of 5.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.19% of the float of Astrazeneca has been sold short.

Short Interest Ratio / Days to Cover

Astrazeneca has a short interest ratio ("days to cover") of 0.89, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Astrazeneca has recently increased by 52.97%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Astrazeneca pays a meaningful dividend of 2.72%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Astrazeneca does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Astrazeneca is 64.87%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Astrazeneca will have a dividend payout ratio of 41.22% next year. This indicates that Astrazeneca will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.88

News Sentiment

Astrazeneca has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for Astrazeneca this week, compared to 8 articles on an average week.

Search Interest

25 people have searched for AZN on MarketBeat in the last 30 days. This is an increase of 47% compared to the previous 30 days.

MarketBeat Follows

15 people have added Astrazeneca to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Astrazeneca insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,211.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

20.35% of the stock of Astrazeneca is held by institutions.

Company Calendar

• Last Earnings: 7/27/2026
• Record date for 9/8 Dividend: 8/07/2026
• Ex-Dividend for 9/8 Dividend: 8/07/2026
• Dividend Payable: 9/08/2026
• Today: 9/11/2026
• Next Earnings (Estimated): 10/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:AZN
• Previous Symbol: NASDAQ:AZN
• CIK: 901832
• Web: astrazeneca.com
• Phone: 011 44 20 7304 5000
• Fax: 44-12-2335-2858
• Employees: 96,100
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Astrazeneca: $206.67
• High Price Target: $216.00
• Low Price Target: $198.00
• Potential Upside/Downside: +29.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.76
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.69
• Trailing P/E Ratio: 23.91
• Forward P/E Ratio: 17.13
• P/E Growth: 1.35
• Net Income: $10.23 billion
• Net Margins: 17.02%
• Pretax Margin: 20.51%
• Return on Equity: 31.45%
• Return on Assets: 13.20%

Debt

• Debt-to-Equity Ratio: 0.47
• Current Ratio: 0.89
• Quick Ratio: 0.67

Sales & Book Value

• Annual Sales: $58.74 billion
• Price / Sales: 4.22
• Cash Flow: $12.95 per share
• Price / Cash Flow: 12.35
• Book Value: $31.41 per share
• Price / Book: 5.09

Miscellaneous

• Outstanding Shares: 1,550,910,000
• Free Float: N/A
• Market Cap: $248.11 billion
• Optionable: N/A
• Beta: 0.25